NEW YORK, July 25 - Affymetrix has named Robert Ellis, who stepped down as CEO of Genometrix just before the company closed its doors June 25, to the position of vice president, product development and quality. 

The company also announced that Barbara Caulfield would be the new vice president and general counsel, replacing Vern Norviel, who has become the new general counsel of subsidiary Perlegen.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.